Venom Based Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
The global venom-based drugs market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of various diseases, and rise in initiatives by government and private organizations, which are curbing the growth of the market. Venom is a compound which is secreted by an animal. It is a poisonous compound which intended to harm or disable their prey or enemy. When venom is produced through organisms, it includes variety of bioactive components which produce toxic effects. Only those active components of these venoms are isolated, purified, and screened which may have desirable therapeutic properties. The other factors supporting the market’s growth are, the extensive research and development, large number of clinical trials, increasing awareness, and government investments, large number of venomous animals, ease in approval of new venom-based drugs, and technological advancements in this field.
Increasing Use of Venom in Numerous Diseases
Venom derived drugs are very useful in treating various diseases such as cancer, heart attack, hypertension, acute coronary syndrome, and other, due to their potential therapeutic values, which propels the growth of the market. Several venom-based drugs are already in use such as captopril, integrilin, reptilase, exanta and others. Moreover, these venom-based drugs are used as diagnostic tools, cosmeceuticals and for drug discovery. For instance, in 2020, a study concluded that bee venom therapy might be useful in treating inflammatory forms of arthritis. Similarly, captopril is a type of drug used to cure high blood pressure and reduce the risk of heart failure after a heart attack. It is derived from a species of pit viper which is found in Brazil.
Technological Advancements and Rise in R&D activities
Owing to rising number of patients suffering from variety of diseases, the surge in demand for the treatment, is augmenting the growth of the market, globally. Various R&D activities are carried by researchers in order to treat these diseases using venom from various animals. The toxins from venom such as proteins, peptides, carbohydrates, and other components are important research tools. Subsequently, other reasons that make animal venoms attractive to researchers across the globe are the specialization, richness, and efficiency of the components present. Also, advancement in genomics, transcriptions and proteomics helps in study of these toxins, which further aids scientists to understand the venoms and their target. For instance, tozuleristide, a diagnostic drug obtained from the venom of the Israeli deathstalker scorpion, is now in clinical trials. An element of the venom, called chlorotoxin, binds to tumor cells. Researchers at the Fred Hutchinson Cancer Research Center re-engineered this protein and attached a fluorescent tag to it, resulting in a diagnostic tool that seeks out and illuminates tumors.
Market Segmentation
The global venom-based drugs market is segmented into animal type, source, therapeutic area, and company. Based on animal type, the market is divided into snake, spider, bee, and others. Based on source, the market is divided into whole venom, synthetic, recombinant, and others. Based on therapeutic area, the market is segmented into hypertension, cardiovascular diseases, neurological disorders, pain management & arthritis, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to extensive research and development on venom based drugs in the country.
Market Players
AstraZeneca Plc., Bristol-Myers Squibb Company, Merck & Co., Inc., Pentapharm Limited Medicure Inc, Millennium Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Elan Pharmaceuticals, Inc., and Beijing Tobishi Pharmaceutical Co., Ltd. are some of the leading companies operating in the market.
Report Scope:
In this report, global venom based drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Venom Based Drugs Market, By Animal Type:
- Snake
- Spider
- Bee
- Others
- Venom Based Drugs Market, By Source:
- Whole Venom
- Synthetic
- Recombinant
- Others
- Venom Based Drugs Market, By Therapeutic Area:
- Hypertension
- Cardiovascular Diseases
- Neurological Disorders
- Pain Management & Arthritis
- Others
- Venom Based Drugs Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in Venom Based Drugs Market
Company Information
- Detailed analysis and profiling of additional market players (up to five).
- 1. Product Overview
- 2. Research Methodology
- 3. Impact of COVID-19 on Global Venom Based Drugs Market
- 4. Executive Summary
- 5. Voice of Customer
- 5.1. Benefits of Using Venom Based Drugs
- 5.2. Commonly Used Animals for Deriving Venom Based Drugs
- 5.3. Demand for Venom Based Drugs, By Therapeutic Area
- 5.4. Barriers to Adoption of Venom Based Drugs
- 6. List of Venom Based Approved Drugs by the FDA
- 7. Clinical Trials Analysis
- 8. Global Venom Based Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Animal Type (Snake, Spider, Bee, Others)
- 8.2.2. By Source (Whole Venom, Synthetic, Recombinant, Others)
- 8.2.3. By Therapeutic Area (Hypertension, Cardiovascular Diseases, Neurological Disorders, Pain Management & Arthritis, Others)
- 8.2.4. By Company (2021)
- 8.2.5. By Region
- 8.3. Market Map
- 9. North America Venom Based Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Animal Type
- 9.2.2. By Source
- 9.2.3. By Therapeutic Area
- 9.2.4. By Country
- 9.3. North America: Country Analysis
- 9.3.1. United States Venom Based Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Animal Type
- 9.3.1.2.2. By Source
- 9.3.1.2.3. By Therapeutic Area
- 9.3.2. Mexico Venom Based Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Animal Type
- 9.3.2.2.2. By Source
- 9.3.2.2.3. By Therapeutic Area
- 9.3.3. Canada Venom Based Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Animal Type
- 9.3.3.2.2. By Source
- 9.3.3.2.3. By Therapeutic Area
- 10. Europe Venom Based Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Animal Type
- 10.2.2. By Source
- 10.2.3. By Therapeutic Area
- 10.2.4. By Country
- 10.3. Europe: Country Analysis
- 10.3.1. France Venom Based Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Animal Type
- 10.3.1.2.2. By Source
- 10.3.1.2.3. By Therapeutic Area
- 10.3.2. Germany Venom Based Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Animal Type
- 10.3.2.2.2. By Source
- 10.3.2.2.3. By Therapeutic Area
- 10.3.3. United Kingdom Venom Based Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Animal Type
- 10.3.3.2.2. By Source
- 10.3.3.2.3. By Therapeutic Area
- 10.3.4. Italy Venom Based Drugs Market Outlook
- 10.3.4.1. Market Size & Forecast
- 10.3.4.1.1. By Value
- 10.3.4.2. Market Share & Forecast
- 10.3.4.2.1. By Animal Type
- 10.3.4.2.2. By Source
- 10.3.4.2.3. By Therapeutic Area
- 10.3.5. Spain Venom Based Drugs Market Outlook
- 10.3.5.1. Market Size & Forecast
- 10.3.5.1.1. By Value
- 10.3.5.2. Market Share & Forecast
- 10.3.5.2.1. By Animal Type
- 10.3.5.2.2. By Source
- 10.3.5.2.3. By Therapeutic Area
- 11. Asia-Pacific Venom Based Drugs Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value
- 11.2. Market Share & Forecast
- 11.2.1. By Animal Type
- 11.2.2. By Source
- 11.2.3. By Therapeutic Area
- 11.2.4. By Country
- 11.3. Asia-Pacific: Country Analysis
- 11.3.1. China Venom Based Drugs Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.1.1. By Value
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Animal Type
- 11.3.1.2.2. By Source
- 11.3.1.2.3. By Therapeutic Area
- 11.3.2. India Venom Based Drugs Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.1.1. By Value
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Animal Type
- 11.3.2.2.2. By Source
- 11.3.2.2.3. By Therapeutic Area
- 11.3.3. Japan Venom Based Drugs Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.1.1. By Value
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Animal Type
- 11.3.3.2.2. By Source
- 11.3.3.2.3. By Therapeutic Area
- 11.3.4. South Korea Venom Based Drugs Market Outlook
- 11.3.4.1. Market Size & Forecast
- 11.3.4.1.1. By Value
- 11.3.4.2. Market Share & Forecast
- 11.3.4.2.1. By Animal Type
- 11.3.4.2.2. By Source
- 11.3.4.2.3. By Therapeutic Area
- 11.3.5. Australia Venom Based Drugs Market Outlook
- 11.3.5.1. Market Size & Forecast
- 11.3.5.1.1. By Value
- 11.3.5.2. Market Share & Forecast
- 11.3.5.2.1. By Animal Type
- 11.3.5.2.2. By Source
- 11.3.5.2.3. By Therapeutic Area
- 12. South America Venom Based Drugs Market Outlook
- 12.1. Market Size & Forecast
- 12.1.1. By Value
- 12.2. Market Share & Forecast
- 12.2.1. By Animal Type
- 12.2.2. By Source
- 12.2.3. By Therapeutic Area
- 12.2.4. By Country
- 12.3. South America: Country Analysis
- 12.3.1. Brazil Venom Based Drugs Market Outlook
- 12.3.1.1. Market Size & Forecast
- 12.3.1.1.1. By Value
- 12.3.1.2. Market Share & Forecast
- 12.3.1.2.1. By Animal Type
- 12.3.1.2.2. By Source
- 12.3.1.2.3. By Therapeutic Area
- 12.3.2. Argentina Venom Based Drugs Market Outlook
- 12.3.2.1. Market Size & Forecast
- 12.3.2.1.1. By Value
- 12.3.2.2. Market Share & Forecast
- 12.3.2.2.1. By Animal Type
- 12.3.2.2.2. By Source
- 12.3.2.2.3. By Therapeutic Area
- 12.3.3. Colombia Venom Based Drugs Market Outlook
- 12.3.3.1. Market Size & Forecast
- 12.3.3.1.1. By Value
- 12.3.3.2. Market Share & Forecast
- 12.3.3.2.1. By Animal Type
- 12.3.3.2.2. By Source
- 12.3.3.2.3. By Therapeutic Area
- 13. Middle East and Africa Venom Based Drugs Market Outlook
- 13.1. Market Size & Forecast
- 13.1.1. By Value
- 13.2. Market Share & Forecast
- 13.2.1. By Animal Type
- 13.2.2. By Source
- 13.2.3. By Therapeutic Area
- 13.2.4. By Country
- 13.3. MEA: Country Analysis
- 13.3.1. South Africa Venom Based Drugs Market Outlook
- 13.3.1.1. Market Size & Forecast
- 13.3.1.1.1. By Value
- 13.3.1.2. Market Share & Forecast
- 13.3.1.2.1. By Animal Type
- 13.3.1.2.2. By Source
- 13.3.1.2.3. By Therapeutic Area
- 13.3.2. Saudi Arabia Venom Based Drugs Market Outlook
- 13.3.2.1. Market Size & Forecast
- 13.3.2.1.1. By Value
- 13.3.2.2. Market Share & Forecast
- 13.3.2.2.1. By Animal Type
- 13.3.2.2.2. By Source
- 13.3.2.2.3. By Therapeutic Area
- 13.3.3. UAE Venom Based Drugs Market Outlook
- 13.3.3.1. Market Size & Forecast
- 13.3.3.1.1. By Value
- 13.3.3.2. Market Share & Forecast
- 13.3.3.2.1. By Animal Type
- 13.3.3.2.2. By Source
- 13.3.3.2.3. By Therapeutic Area
- 14. Market Dynamics
- 14.1. Drivers
- 14.2. Challenges
- 15. Market Trends & Developments
- 16. Competitive Landscape
- 16.1. AstraZeneca Plc.
- 16.2. Bristol-Myers Squibb Company
- 16.3. Merck & Co., Inc.
- 16.4. Pentapharm Limited
- 16.5. Medicure Inc
- 16.6. Millennium Pharmaceuticals, Inc.
- 16.7. Bausch Health Companies, Inc.
- 16.8. Novartis AG
- 16.9. Elan Pharmaceuticals, Inc.
- 16.10. Beijing Tobishi Pharmaceutical Co., Ltd.
- 17. Strategic Recommendations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook